2025-07-29 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals Inc. (RXRX) based on the information you provided, presented in a structured report format.

## Recursion Pharmaceuticals Inc. (RXRX) Analysis

**Ticker:** RXRX
**Company Description:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to discover and develop novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

*   **RXRX Cumulative Return:** -41.62%
*   **VOO (S&P 500) Cumulative Return:** 38.73%
*   **Absolute Divergence (End Date):** -78.7%
*   **Divergence Range (Max-Min):** (35.8%, -88.1%)
*   **Relative Divergence:** 7.6 (Indicates the current divergence is at the 7.6th percentile of its historical range)

**Analysis:** RXRX has significantly underperformed the S&P 500. The relative divergence suggests the underperformance is near its historical worst, but the company revenue 및 Profitability, Capital and Profitability가 좋지 않다.

**Alpha, Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha  | Beta  | Cap(B) |
|------------|-------|-------|--------|-------|--------|
| 2021-2023  | 5.0%  | 73.6% | -1.0%  | -0.1  | 4.3    |
| 2022-2024  | 0.0%  | 73.6% | -25.0% | 0.1  | 2.9    |
| 2023-2025  | 10.0% | 73.6% | -42.0% | 0.1 | 2.7    |

**Analysis:**

*   **CAGR:**  The Compound Annual Growth Rate varies.
*   **MDD:** The Maximum Drawdown is consistently high.
*   **Alpha:** Alpha is negative, indicating underperformance relative to the benchmark. This means RXRX hasn't generated excess returns.
*   **Beta:**  Beta is close to zero, suggesting RXRX's price movements are not strongly correlated with the market. This low beta suggests RXRX's price movements are relatively independent of broader market trends.
*   **Cap:** The company's market capitalization is in the billions.

### 2. Recent Price Action

*   **Last Price:** 6.31
*   **Previous Close:** 6.49
*   **Change:** -2.77%
*   **5-Day Moving Average:** 6.406
*   **20-Day Moving Average:** 5.662
*   **60-Day Moving Average:** 5.0497

**Analysis:**  The price closed lower than the previous day, with the 5-day moving average above the 20-day and 60-day moving averages, indicating a short-term uptrend. However, the recent drop suggests potential short-term weakness.

### 3. Technical Indicators & Risk

*   **MRI (Market Risk Indicator):** 0.3286 (Low Risk)
*   **RSI (Relative Strength Index):** 66.61 (Approaching overbought territory)
*   **PPO (Percentage Price Oscillator):** 1.30
*   **Hybrid Signal:**  cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34) (Cash Ratio: 0% on 2025-07-08)
*   **Recent (20-day) Relative Divergence Change:** 2.5 (+) (Short-term increase in relative performance)
*   **Expected Return (%):** -311.5% (Long-term underperformance relative to S&P 500)

**Analysis:**

*   The MRI suggests low market risk.
*   The RSI indicates the stock is nearing overbought conditions, which might signal a potential pullback.
*   The PPO indicates a potential uptrend.
*   The recent price drop suggests potential short-term weakness. The Hybrid Signal recommends a cautious buy.
*   The large negative expected return is concerning, suggesting significant underperformance relative to the S&P 500 over a long-term investment horizon.
*   The negative change indicates the market is reacting negatively to recent events. The recent price drop of -2.77% reflects some negative market sentiment.

### 4. Recent News & Events

*   **2025-07-25:** Major business developments, regulatory changes, or market events.
*   **2025-07-27:** Analyst discussion of performance, industry trends, and global economic factors.
*   **2025-07-28:** Notable stock volatility due to news, earnings reports, or executive actions.
*   **2025-07-29:** Market experts highlight risks and opportunities; investors advised to monitor news.

**Analysis:**  The news indicates RXRX is experiencing significant events causing volatility. It's crucial to investigate these events further to understand their impact.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-05-05 | -0.50 | 0.01 B$ |
| 2024-11-06 | -0.34 | 0.03 B$ |
| 2024-08-08 | -0.40 | 0.01 B$ |
| 2024-05-09 | -0.39 | 0.01 B$ |
| 2025-05-05 | -0.39 | 0.01 B$ |

**Analysis:**

*   The company consistently reports negative Earnings Per Share (EPS).
*   Revenue is relatively low. This suggests that, while the company might have promising technology, it's struggling to generate substantial revenue or achieve profitability.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-03-31   | $0.01B  | -47.31%       |
| 2024-12-31   | $0.00B  | -183.62%      |
| 2024-09-30   | $0.03B  | 53.69%        |
| 2024-06-30   | $0.01B  | 36.14%        |
| 2024-03-31   | $0.01B  | 17.23%        |

**Capital and Profitability:**

| Quarter      | Equity  | ROE       |
|--------------|---------|-----------|
| 2025-03-31   | $0.93B  | -21.68%   |
| 2024-12-31   | $1.03B  | -17.29%   |
| 2024-09-30   | $0.52B  | -18.27%   |
| 2024-06-30   | $0.58B  | -16.69%   |
| 2024-03-31   | $0.40B  | -22.78%   |

**Analysis:**

*   **Revenue:**  Revenue is inconsistent, with a period of high revenue offset by lower periods.
*   **Profit Margin:**  Profit margins are highly variable, with significant losses in some quarters.
*   **Equity:** The company has a substantial equity base.
*   **ROE (Return on Equity):**  ROE is consistently negative, indicating the company is not generating profits from its equity.

### 7. Overall Summary

Recursion Pharmaceuticals (RXRX) presents a mixed picture.  It is a biotechnology company with promising technology, as indicated by its market capitalization. However, the company is facing significant challenges:

*   **Underperformance:** RXRX has significantly underperformed the S&P 500, and its expected return is highly negative.
*   **Financials:** The company is not profitable, with negative EPS, inconsistent revenue, and negative ROE.
*   **Volatility:** Recent news indicates volatility.
*   **Technicals:**  The RSI is nearing overbought, and the moving averages indicate a potential uptrend that may be reversing.

**Recommendation:** Due to significant underperformance, negative financials, and high volatility, caution is advised. Investors should conduct thorough due diligence, investigate the recent news and events, and carefully consider their risk tolerance before investing in RXRX. The long-term negative expected return is a major red flag.

